Last reviewed · How we verify

Amodiaquine+Sulfadoxine/Pyrimethamine — Competitive Intelligence Brief

Amodiaquine+Sulfadoxine/Pyrimethamine (Amodiaquine+Sulfadoxine/Pyrimethamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

phase 3 Antimalarial combination Parasite dihydrofolate reductase, dihydropteroate synthase, hemoglobin metabolism Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Amodiaquine+Sulfadoxine/Pyrimethamine (Amodiaquine+Sulfadoxine/Pyrimethamine) — University of California, San Francisco. This combination drug inhibits parasite dihydrofolate reductase and dihydropteroate synthase enzymes while disrupting parasite hemoglobin metabolism to treat malaria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amodiaquine+Sulfadoxine/Pyrimethamine TARGET Amodiaquine+Sulfadoxine/Pyrimethamine University of California, San Francisco phase 3 Antimalarial combination Parasite dihydrofolate reductase, dihydropteroate synthase, hemoglobin metabolism
chlorproguanil-dapsone plus artesunate chlorproguanil-dapsone plus artesunate Centers for Disease Control and Prevention marketed Antimalarial combination Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate)
IPTp-SP IPTp-SP Kenya Medical Research Institute marketed Antifolate antimalarial combination Dihydrofolate reductase (DHFR)
IPTp-DP IPTp-DP Kenya Medical Research Institute marketed Antimalarial combination therapy Plasmodium falciparum (malaria parasite)
arthemether + lumefantrine arthemether + lumefantrine Sanofi marketed Antimalarial combination Plasmodium falciparum heme detoxification pathway; artemisinin-derived endoperoxide bridge
Amodiaquine plus sulphadoxine-pyrimethamine combination Amodiaquine plus sulphadoxine-pyrimethamine combination Centre for Global Health Research, Ghana marketed Antimalarial combination Plasmodium dihydrofolate reductase, dihydropteroate synthase, and hemozoin formation
Sulfadoxine-pyrimethamine plus artesunate Sulfadoxine-pyrimethamine plus artesunate London School of Hygiene and Tropical Medicine marketed Antimalarial combination Dihydrofolate reductase, dihydropteroate synthase (sulfadoxine-pyrimethamine); mitochondrial electron transport (artesunate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

  1. Centers for Disease Control and Prevention · 4 drugs in this class
  2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
  3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
  4. Sanofi · 2 drugs in this class
  5. Menzies School of Health Research · 2 drugs in this class
  6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
  7. Epicentre · 1 drug in this class
  8. Jhpiego · 1 drug in this class
  9. Charite University, Berlin, Germany · 1 drug in this class
  10. Ifakara Health Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amodiaquine+Sulfadoxine/Pyrimethamine — Competitive Intelligence Brief. https://druglandscape.com/ci/amodiaquine-sulfadoxine-pyrimethamine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: